Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease
NCT03298399Phase 1Withdrawn
- Sponsor
- Emory University
- Start
- Dec 2017
- Primary completion
- Oct 2018
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label trial of EPIC2016-MSC003 in sickle cell disease (SCD) (3 arms), sponsored by Emory University. Primary endpoint: Safety and tolerability of EPIC2016-MSC003 based upon dose limiting toxicities (DLTs). Planned start Dec 2017; status: withdrawn.
02
Drugs
EPIC2016-MSC003
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03298399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298399.